Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DHA-paclitaxel

Next Previous
Drug Profile

DHA-paclitaxel

Alternative Names: Paclitaxel-DHA conjugate; Paclitaxel-docosahexaenoic acid conjugate; Taxoprexin

Latest Information Update: 04 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luitpold Pharmaceuticals
  • Class Antineoplastics; Paclitaxels; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours

Most Recent Events

  • 02 Jan 2019 Luitpold Pharmaceuticals is now called American Regent
  • 24 Jun 2018 Biomarkers information updated
  • 08 May 2017 Luitpold Pharmaceuticals terminated a phase II trial in Liver cancer and biliary cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA as the sponsor suspended the development of the drug (IV-infusion) (NCT00422877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top